重症/危重症2019新型冠状病毒奥密克戎变异株感染合并心房颤动的临床分析
研究纳入2022年3月23日至5月15日上海市周浦医院2675例≥50岁新冠奥密克戎感染者,按症状分为轻症组、普通组和重症/危重症组,比较三组临床资料、影像和实验室结果及预后。房颤发生率5.05%(135/2675),房颤患者中位年龄84.0(74.0,89.0)岁。重症/危重症组合并发热、肝肾功能不全、2型糖尿病比例及心衰NYHA分级均高于轻症和普通组,CRP、ALT、AST、CK-MB更高,Hb和ALB更低。房颤患者死亡率18.5%(25/135),均为危重症患者,多器官衰竭、心衰、猝死、呼吸衰竭和栓塞性疾病是主要死因。
要点
- ≥50岁新冠奥密克戎感染者房颤发生率为5.05%(135/2675),房颤患者中位年龄84.0(74.0,89.0)岁,年龄范围55~101岁。
- 重症/危重症房颤患者死亡率18.5%(25/135),死亡者均为危重症患者;轻症组、普通组及9例重症患者均无死亡记录。
- 死亡原因:多器官衰竭40.0%(10/25,其中40.0%合并消化道出血)、心衰20.0%(5/25)、呼吸衰竭12.0%(3/25),32.0%(8/25)合并脑栓塞、肺栓塞和脑出血。
- 重症/危重症组心衰NYHA分级1.8±1.1,高于轻症组1.1±0.8和普通组1.2±0.7(均P<0.05);CRP 27.2(6.0,60.8)mg/L、ALT 31.3±15.4 U/L、AST 78.0±21.7 U/L均高于轻症和普通组(均P<0.05)。
- 重症/危重症组抗血小板药物使用比例最低(27.0%),低分子肝素使用比例81.1%(30/37)高于轻症组51.5%(35/68)(P<0.05)。
适用人群与场景
- 2022年3月23日至5月15日入住上海市新冠定点医院周浦医院的≥50岁新冠奥密克戎感染者2675例,其中合并房颤者135例。
- 按症状分为轻症组(68例)、普通组(30例)、重症/危重症组(37例,其中重症9例、危重症28例)。
处置流程与药物剂量
- 重症/危重症组抗血小板药物使用比例为27.0%,为三组中最低;低分子肝素使用比例为81.1%(30/37),高于轻症组的51.5%(35/68)(P<0.05)。
研究设计与关键结果
- 研究类型为临床分析,纳入2675例≥50岁新冠奥密克戎感染者,房颤发生率5.05%(135/2675),房颤患者中位年龄84.0(74.0,89.0)岁。
- 重症/危重症组中55~75岁占43.2%,新冠疫苗接种率32.4%;新发房颤在三组中最高,但持续性房颤在轻症组比例最高(58.8%)。
- 重症/危重症组合并发热29.7%、肝功能不全13.5%、肾功能不全46.0%、2型糖尿病46.0%,心衰NYHA分级1.8±1.1,高于轻症组1.1±0.8和普通组1.2±0.7(均P<0.05)。
- 重症/危重症组CRP 27.2(6.0,60.8)mg/L、ALT 31.3±15.4 U/L、AST 78.0±21.7 U/L,均高于轻症组[CRP 7.6(3.1,19.3)mg/L、ALT 15.4±9.3 U/L、AST 34.7±15.6 U/L]和普通组[CRP 12.8(4.9,26.3)mg/L、ALT 19.3±11.7 U/L、AST 38.1±24.4 U/L](均P<0.05)。
- 重症/危重症组Hb 105.3±22.5 g/L、ALB 33.7±6.0 g/L,低于轻症组(Hb 125.8±25.4 g/L、ALB 39.0±5.5 g/L)和普通组(Hb 123.0±20.4 g/L、ALB 39.6±13.1 g/L)(均P<0.05)。
- 重症/危重症组CK-MB 2.5(1.5,3.4)μg/L,高于轻症组的2.2(1.2,2.8)μg/L(P<0.05)。
- 房颤患者死亡率18.5%(25/135),死亡者均为危重症患者;32.0%(8/25)合并脑栓塞、肺栓塞和脑出血;40.0%(10/25)死于多器官衰竭(其中40.0%合并消化道出血),20.0%(5/25)死于心衰,12.0%(3/25)死于呼吸衰竭;轻症组、普通组及9例重症患者均无死亡记录。
证据类型、等级与局限
- 证据类型:临床分析(单中心观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,合并房颤的新冠奥密克戎重症/危重症患者预后较差、死亡率高,多器官衰竭、心衰、猝死、呼吸衰竭和栓塞性疾病是主要死亡原因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the clinical characteristics and prognosis of coronavirus disease 2019 (COVID-19) patients with Omicron variant combined with atrial fibrillation (AF).
METHODS: From March 23, 2022 to May 15, 2022, 2 675 aged ≥ 50 years old COVID-19 patients with AF were admitted to Zhoupu Hospital, the designated hospital for COVID-19 in Shanghai. Patients were divided into mild symptoms group, normal group, and serious/critical group according to the symptoms. The clinical data, imaging examination and laboratory results and prognosis of the three group patients were compared.
RESULTS: The median age of 2 675 COVID-19 patients was 69.0 (60.0, 81.0) years old, the incidence of AF was 5.05% (135/2 675), the age range of AF patients were from 55 to 101 years old, with a median age of 84.0 (74.0, 89.0), and the number of mild symptoms, normal, serious/critical patients were 68, 30, 37, respectively, including 9 of serious and 28 of critical patients. In the serious/critical patients, aged 55-75 years old accounted for 43.2%, the rate of 2019 novel coronavirus vaccination was 32.4%. The identified new-onset AF was the highest among the three groups, but the rate of persistent AF was the highest in the mild symptoms group (58.8%). The severe/critical group complicated with fever (29.7%), hepatic insufficiency (13.5%), renal insufficiency (46.0%), type 2 diabetes (46.0%), and heart failure were higher in NYHA classification [compared with the mild symptoms and normal group (score): 1.8±1.1 vs. 1.1±0.8, 1.2±0.7, respectively, all P < 0.05]. In term of laboratory examinations, C-reactive protein (CRP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels were significantly higher in serious/critical patients compared to the mild symptoms and normal groups [CRP (mg/L): 27.2 (6.0, 60.8) vs. 7.6 (3.1, 19.3), 12.8 (4.9, 26.3), ALT (U/L): 31.3±15.4 vs. 15.4±9.3, 19.3±11.7, AST (U/L): 78.0±21.7 vs. 34.7±15.6, 38.1±24.4, all P < 0.05]. The hemoglobin (Hb) and albumin (ALB) levels were significantly lower than those in the mild symptoms and normal groups [Hb (g/L): 105.3±22.5 vs. 125.8±25.4, 123.0±20.4, ALB (g/L): 33.7±6.0 vs. 39.0±5.5 and 39.6±13.1, all P < 0.05]. In addition, MB isoenzyme of creatine kinase (CK-MB) was significantly higher in the serious/critical group than that in the mild symptoms group [μg/L: 2.5 (1.5, 3.4) vs. 2.2 (1.2, 2.8), P < 0.05]. In terms of the treatment, the percentage of antiplatelet agents and low-molecular heparin ratio compared among the three groups were statistically significant, with the serious/critical group using the lowest percentage of antiplatelet agents (27.0%) and a higher percentage of low-molecular heparin usage than that in mild symptoms group [81.1% (30/37) vs. 51.5% (35/68), P < 0.05]. In terms of prognosis, the mortality of patients with AF was 18.5% (25/135), all of whom were critical ill, including 32.0% (8/25) with cerebral embolism, pulmonary embolism and cerebral hemorrhage. Among them, 40.0% (10/25) died of multiple organ failure (40.0% combined with gastrointestinal hemorrhage), 20.0% (5/25) died of heart failure, and 12.0% (3/25) died of respiratory failure; while there were no death cases recorded in the mild symptoms, normal group and 9 serious patients.
CONCLUSIONS: The serious/critical patients infected with COVID-19 Omicron variant with AF, have a worse prognosis and high mortality. Multiple organ failure, heart failure, sudden cardiac death, respiratory failure and embolic disease are the major causes of death.
参考来源
- Zhao Z, Wang S, Zhu L, et al. [Clinical analysis of severe/critical 2019 novel coronavirus Omicron variant infection combined with atrial fibrillation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36377440. doi:10.3760/cma.j.cn121430-20220804-00712
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。